Abbvie Inc

NYSE:ABBV   3:59:59 PM EDT
115.85
+0.45 (+0.39%)
4:00:00 PM EDT: $115.83 -0.02 (-0.02%)
Products, Regulatory

Abbvie Inc Says Phase 3 Maintenance Results Show Patients With Crohn's Disease Receiving Risankizumab (Skyrizi) Achieved Endoscopic Response And Clinical Remission At One Year

Published: 06/02/2021 12:35 GMT
Abbvie Inc (ABBV) - Abbvie Inc - Phase 3 Maintenance Results Show Patients With Crohn's Disease Receiving Risankizumab (skyrizi®) Achieved Endoscopic Response and Clinical Remission at One Year.
Abbvie Inc - Overall Safety Results in This Study Were Generally Consistent With Known Safety Profile of Risankizumab, With No New Safety Risks Observed1-7.
Abbvie Inc - Positive Top-line Results From Phase 3 Maintenance Study, Fortify, Showing Risankizumab 360 Mg Achieved Co-primary Endpoints.